AstraZeneca gets a green light on Imfinzi for small-cell lung cancer — setting the stage for a battle with Roche's Tecentriq
The standard-of-care for small-cell lung cancer (SCLC) for decades was platinum-based chemotherapy, but that paradigm shifted in 2018, with the approval of Bristol Myers Squibb’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
